Review



sch58621 a 2a ar antagonist  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Tocris sch58621 a 2a ar antagonist
    The effects of the adenosine receptor A 2A antagonist <t>SCH58621,</t> adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.
    Sch58621 A 2a Ar Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch58621+a+2a+ar+antagonist/sch58621+a2aar+antagonist/pmc11727715-107-27-44
    Average 90 stars, based on 1 article reviews
    sch58621 a 2a ar antagonist - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine"

    Article Title: Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms252413343

    The effects of the adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.
    Figure Legend Snippet: The effects of the adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.

    Techniques Used:

    Representative images of 2D capillary-like tube formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 100 μΜ.
    Figure Legend Snippet: Representative images of 2D capillary-like tube formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 100 μΜ.

    Techniques Used:

    Representative images of 3D spheroid sprout formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 200 μM.
    Figure Legend Snippet: Representative images of 3D spheroid sprout formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 200 μM.

    Techniques Used:

    Related Articles

    other:

    Article Title: Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine
    Article Snippet: Adenosine, DPCPX (A 1 AR antagonist), 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled acetylated LDL (DiI-ac-LDL), and adenosine deaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA), and MRS1220 (A 3 AR antagonist), SCH58621 (A 2A AR antagonist), and MRS1706 (A 2B AR inverse agonist and antagonist) were purchased from Tocris Bioscience (Bristol, UK).



    Similar Products

    sch58621 a 2a ar antagonist  (Tocris)
    90
    Tocris sch58621 a 2a ar antagonist
    The effects of the adenosine receptor A 2A antagonist <t>SCH58621,</t> adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.
    Sch58621 A 2a Ar Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sch58621+a+2a+ar+antagonist/sch58621+a2aar+antagonist/pmc11727715-107-27-44
    Average 90 stars, based on 1 article reviews
    sch58621 a 2a ar antagonist - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The effects of the adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.

    Journal: International Journal of Molecular Sciences

    Article Title: Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine

    doi: 10.3390/ijms252413343

    Figure Lengend Snippet: The effects of the adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706 on capillary-like tube formation by ( A ) ECFCs and ( B ) HUVECs, and on spheroid sprout formation by ( C ) ECFCs and ( D ) HUVECs, induced by ticagrelor, adenosine, and their combination. The values represent the means ± SDs from at least 6 independent biological replicates each performed in 2 technical replicates. * p < 0.02 and ** p < 0.01 compared to ticagrelor, adenosine, or their combination in the absence of SCH58621 and MRS1706. # p < 0.05 compared to ticagrelor, adenosine, or their combination in the presence of either SCH58621 or MRS1706. HUVECs: human umbilical vein endothelial cells, ECFCs: endothelial colony-forming cells.

    Article Snippet: Adenosine, DPCPX (A 1 AR antagonist), 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled acetylated LDL (DiI-ac-LDL), and adenosine deaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA), and MRS1220 (A 3 AR antagonist), SCH58621 (A 2A AR antagonist), and MRS1706 (A 2B AR inverse agonist and antagonist) were purchased from Tocris Bioscience (Bristol, UK).

    Techniques:

    Representative images of 2D capillary-like tube formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 100 μΜ.

    Journal: International Journal of Molecular Sciences

    Article Title: Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine

    doi: 10.3390/ijms252413343

    Figure Lengend Snippet: Representative images of 2D capillary-like tube formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 100 μΜ.

    Article Snippet: Adenosine, DPCPX (A 1 AR antagonist), 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled acetylated LDL (DiI-ac-LDL), and adenosine deaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA), and MRS1220 (A 3 AR antagonist), SCH58621 (A 2A AR antagonist), and MRS1706 (A 2B AR inverse agonist and antagonist) were purchased from Tocris Bioscience (Bristol, UK).

    Techniques:

    Representative images of 3D spheroid sprout formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 200 μM.

    Journal: International Journal of Molecular Sciences

    Article Title: Ticagrelor Induces Angiogenesis in Progenitor and Mature Endothelial Cells In Vitro: Investigation of the Possible Role of Adenosine

    doi: 10.3390/ijms252413343

    Figure Lengend Snippet: Representative images of 3D spheroid sprout formation by ECFCs that were treated with ticagrelor, adenosine, and their combination in the presence of adenosine receptor A 2A antagonist SCH58621, adenosine receptor A 2B inverse agonist, and antagonist MRS1706. Scale bar 200 μM.

    Article Snippet: Adenosine, DPCPX (A 1 AR antagonist), 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled acetylated LDL (DiI-ac-LDL), and adenosine deaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA), and MRS1220 (A 3 AR antagonist), SCH58621 (A 2A AR antagonist), and MRS1706 (A 2B AR inverse agonist and antagonist) were purchased from Tocris Bioscience (Bristol, UK).

    Techniques: